Effects of bosentan on nondigital ulcers in patients with systemic sclerosis
Effects of bosentan on nondigital ulcers in patients with systemic sclerosis
复制标题
波生坦对系统性硬化症患者非指溃疡的影响
DOI：
10.1111/j.1365-2133.2011.10581.x
复制
发表时间：
2012
影响因子：
10.3
通讯作者：
S. Sato
中科院分区：
文献类型：
--
作者：
Tadatsugu Taniguchi;Y. Asano;Masaru Hatano;Z. Tamaki;M. Tomita;T. Kawashima;M. Miyazaki;H. Sumida;K. Akamata;Takehiro Takahashi;Y. Ichimura;T. Toyama;M. Sugita;S. Noda;Atsushi Yao;K. Kinugawa;S. Sato
波生坦是一种口服双重内皮素受体拮抗剂，在两项高质量的随机对照试验中，已证明其可有效预防系统性硬化症（SSc）患者新发指端溃疡。然而，其对SSc非指溃疡的疗效仍不清楚。
Background Bosentan is an oral dual endothelin receptor antagonist, which has been shown to be efficacious for preventing new digital ulcers in patients with systemic sclerosis (SSc) in two high‐quality randomized controlled trials. However, its efficacy for nondigital ulcers in SSc remains unknown.